Form 4: Neuronetics Director Sasha Cucuz Receives RSU Grant

Director Sasha Cucuz was granted 30,000 restricted stock units by Neuronetics, Inc. as part of an equity compensation award.

Summary

• Director Sasha Cucuz acquired 30,000 restricted stock units (RSUs) on May 28, 2026.
• Each RSU represents a contingent right to receive one share of common stock.
• The award vests on the earlier of May 28, 2027, or the director's separation of service or a change in control of the company.
• Following this transaction, the reporting person holds 1,542,798 shares directly.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this as a routine administrative filing regarding director compensation with no material impact on company operations or financial health.

Positives

• Alignment of director interests with shareholders through equity-based compensation.

Negatives

• None identified in this filing.

Risks

• Vesting is subject to continuous service requirements.

Future Outlook

The RSU award is expected to vest on May 28, 2027, provided the director remains in continuous service.

Industry Context

StockSavvy.ai notes that equity grants to board members are standard corporate governance practices designed to incentivize long-term oversight and alignment with shareholder value in the medical device sector.

Comparison to Industry Standards

• The use of RSU grants for non-employee directors is consistent with standard compensation practices for publicly traded medical technology companies.

Related Party Transactions

• The reporting person disclaims beneficial ownership of shares held by Greybrook Realty Partners Inc. and Greybrook Health Inc. except to the extent of his pecuniary interest.

Stakeholder Impact

• Minimal impact on shareholders as this is a standard equity compensation event.

Next Steps

• Vesting of the RSU award on May 28, 2027.

Key Dates

Keywords

Neuronetics, STIM, Form 4, Insider Trading, Equity Compensation, Director Ownership